What is Captor Therapeutics Spolka Akcyjna's (CTX.WA) StockRank?

MoatMap's StockRank for Captor Therapeutics Spolka Akcyjna (CTX.WA) is 6/100, with a Strong Sell signal. This is a composite score combining Quality (15), Value (20), and Momentum (40) factor ranks across MoatMap's universe of 25,000+ stocks.

Does Captor Therapeutics Spolka Akcyjna have an economic moat?

Captor Therapeutics Spolka Akcyjna (CTX.WA) has a Quality factor score of 15/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Captor Therapeutics Spolka Akcyjna a buy, hold, or sell?

MoatMap's current signal for Captor Therapeutics Spolka Akcyjna (CTX.WA) is Strong Sell, based on a StockRank of 6/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is Captor Therapeutics Spolka Akcyjna in?

Captor Therapeutics Spolka Akcyjna (CTX.WA) operates in the Healthcare sector, specifically the Biotechnology industry (Poland).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

CTX.WA

Strong SellSinker

Captor Therapeutics Spolka Akcyjna · Healthcare · Poland · $120M · Avg Vol: $75K/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-128.9%

D/E

0.3x

Dividend %

—

COMPANY DESCRIPTION

Captor Therapeutics S.A. is a biopharmaceutical company specializing in the development of targeted protein degradation (TPD) drugs to treat cancer and autoimmune diseases. The company's competitive advantage lies in its proprietary OptiDeg platform, which enables the discovery of novel degrader molecules. It is a cutting-edge biotechnology player in the rapidly growing field of protein degradation.

FINANCIAL SUMMARY (PLN)

Year	2021	2022	2023	2024	2025	CAGR	TTM	2026E	2027E	Fwd CAGR
Revenue	4.0M	9.2M	13.2M	15.8M	4.7M	4.0%	2.4M	56.7M	10.0M	46.5%
EPS (PLN)	-7.89	-8.61	-15.19	-8.25	-7.61	—	-7.76	—	—	—
Shares	4.1M	4.2M	4.6M	5.5M	5.5M	+33.4%	6.3M	—	—	—
Debt	8.2M	7.0M	3.8M	5.6M	3.6M	-18.7%	3.2M	—	—	—
Equity	124.2M	96.3M	69.2M	64.5M	23.5M	-34.1%	—	—	—	—
Op CF	-28.5M	-22.9M	-52.2M	-31.9M	-37.3M	—	-73.0M	—	—	—
Inv CF	-5.1M	-17.6M	19.9M	0.3M	-19.9M	—	—	—	—	—
Fin CF	140.9M	-6.3M	36.9M	-4.8M	28.6M	—	—	—	—	—

Loading 1Y...

PRICE (1Y)-3.5%

SMA 50SMA 200

$19.39

RSI (14)

46.2

52W High

$24.02

From 52W High

0.8%

SCORE BREAKDOWN

Quality

ROIC

-56.4%14.0

ROE

-128.9%6.8

GP/Assets

2.0%14.2

Op. Margin

-3433.5%4.2

FCF/Assets

-30.4%13.6

Piotroski

25.9

Int. Cover

-50.0x5.9

D/E Ratio

0.26x44.3

Current Ratio

1.60x29.4

Value

P/E (TTM)

—N/A

EV/EBITDA

-10.9x25.0

P/FCF

—N/A

P/B

32.8x3.2

P/S

189.6x5.0

Div Yield

—N/A

Momentum

52W High %

81%68.5

RS 6M

-46%15.4

SMA 50/200

0.96x45.9

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$120M

P/E (Forward)

-11.1x

Gross Margin

76.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CTX.WA are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
CTX.WA	Captor Therapeutics Spolka Akcyjna(you)	$120M	6	Strong Sell
RVU.WA	Ryvu Therapeutics S.A.	$113M	4	Strong Sell
S2B.WA	Syn2bio S.A.	$148M	3	Strong Sell
BCX.WA	Bioceltix S.A.	$118M	18	Strong Sell
SVE.WA	Synthaverse S.A.	$46M	11	Strong Sell
MAB.WA	Mabion S.A.	$34M	10	Strong Sell
MOC.WA	Molecure S.A.	$40M	14	Strong Sell
PTG.WA	Poltreg S.A.	$34M	13	Strong Sell
NNG.WA	NanoGroup S.A.	$28M	14	Strong Sell
URT.WA	Urteste S.A.	$18M	12	Strong Sell

Peer medians: ROE -16.3% · P/E 17.0x · Gross margin 30.1%

Captor Therapeutics Spolka Akcyjna (CTX.WA): Stock Score Summary

Captor Therapeutics Spolka Akcyjna (CTX.WA) has a MoatMap StockRank of 6/100 based on Quality (15/100), Value (20/100), and Momentum (40/100) factor scores. The current signal is STRONG SELL.

Key Financial Metrics

Price	$19.39
Market Cap	$120M
P/E (Forward)	-11.11
Price/Book	32.84
Return on Equity	-128.9%
Return on Invested Capital	-56.4%
Debt/Equity	0.26x
Gross Margin	76.0%
Operating Margin	-3433.5%
Revenue Growth	-87.4%
Free Cash Flow	$-7M

Captor Therapeutics Spolka Akcyjna operates in the Biotechnology industry, part of the Healthcare sector (Poland).

Frequently Asked Questions

What is Captor Therapeutics Spolka Akcyjna’s (CTX.WA) StockRank?: MoatMap’s StockRank for Captor Therapeutics Spolka Akcyjna (CTX.WA) is 6/100, with a Strong Sell signal. It is a composite of Quality (15), Value (20), and Momentum (40) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does Captor Therapeutics Spolka Akcyjna have an economic moat?: Captor Therapeutics Spolka Akcyjna (CTX.WA) has a Quality factor score of 15/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Captor Therapeutics Spolka Akcyjna a buy, hold, or sell?: MoatMap’s current signal for Captor Therapeutics Spolka Akcyjna (CTX.WA) is Strong Sell, based on a StockRank of 6/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is Captor Therapeutics Spolka Akcyjna in?: Captor Therapeutics Spolka Akcyjna (CTX.WA) operates in the Healthcare sector, specifically the Biotechnology industry (Poland).